KZIA רווח למניה בשנים עשר החודשים האחרונים Kazia

The 12-month EPS change reflects profit dynamics, where the current status is -6.89. Medium-term growth is expected following the results of final-stage clinical trials. Kazia Therapeutics (KZIA) generates revenue by developing drugs to treat complex brain tumors. Patent protection ensures a stable cash flow due to the lack of alternative therapies for patients.
Kazia Therapeutics - פילוחים אנליטיים ומדדי מפתח (KZIA)

Kazia Therapeutics (KZIA) focuses on costly R&D developments of anti-tumor agents without current sales. Mathematically, this is reflected in a negative net income value distributed across the total volume of issued shares. This metric measures the business's actual ability to generate income, stripped of the influence of leverage. Analyzing the current level of the moving average earnings per share allows for an assessment of the capital burn rate. The trend of the curve here serves as an indicator of the company's survivability during the clinical trial period.